|
|
Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.
According to the FDA, adverse drug events harmed or killed approximately 1,200,000 people in the United States in the year 2015.
After 5 years of being diagnosed with rheumatoid arthritis, one every three patients will no longer be able to work.
On average, someone in the United States has a stroke about every 40 seconds. This is about 795,000 people per year.
Less than one of every three adults with high LDL cholesterol has the condition under control. Only 48.1% with the condition are being treated for it.